The global sickle cell disease treatment market size was valued at USD 2.1 billion in 2017 and is anticipated to exhibit a CAGR of 14.3% during the forecast period. Sickle cell disease (SCD) is a hereditary blood disorder characterized by abnormal, rigid, sickle-shaped red blood cells (RBCs) caused due to mutations in the beta-globin gene. Severity of the disease varies widely from person to person.
Sie sind vermutlich noch nicht im Forum angemeldet - Klicken Sie hier um sich kostenlos anzumelden